Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference24 articles.
1. Furukawa Y, Vu HA, Akutsu M, Odgerel T, Izumi T, Tsunoda S, Matsuo Y, Kirito K, Sato Y, Mano H, Kano Y (2007) Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines. Leukemia 21(5):1005–1014. https://doi.org/10.1038/sj.leu.2404593
2. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, Campochiaro P, Wood J, O’Reilly T, Meyer T (2000) PKC412–a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 15(1):17–28
3. Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T, Gilliland DG, Griffin JD (2002) Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1(5):433–443. https://doi.org/10.1016/s1535-6108(02)00069-7
4. Tvedt TH, Nepstad I, Bruserud O (2017) Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells. Expert Opin Investig Drugs 26(3):343–355. https://doi.org/10.1080/13543784.2017.1275564
5. Rydapt (midostaurin) [package insert] (2019) East Hanover, NJ: Novartis Pharmaceuticals Corporation
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献